CDKN2A antibody (AA 39-65)

Catalog No. ABIN3030639

Product Details anti-CDKN2A Antibody

Target: CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A))

Binding Specificity: AA 39-65

Reactivity: Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CDKN2A antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Purification: Antigen affinity purified

Immunogen: A portion of amino acids 39-65 from the mouse protein was used as the immunogen for this Cdkn2a antibody.

Isotype: Ig Fraction

Application Details

Application Notes: Titration of the Cdkn2a antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the Cdkn2a antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Target Details for CDKN2A

Target: CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A))

Alternative Name: Cdkn2a (CDKN2A Products)

Synonyms: Arf antibody, p16 antibody, MTS1 antibody, INK4A antibody, p19ARF antibody, p16Cdkn2a antibody, ARF antibody, CDK4I antibody, CDKN2 antibody, CMM2 antibody, INK4 antibody, MLM antibody, MTS-1 antibody, P14 antibody, P14ARF antibody, P16 antibody, P16-INK4A antibody, P16INK4 antibody, P16INK4A antibody, P19 antibody, P19ARF antibody, TP16 antibody, ARF-INK4a antibody, INK4a-ARF antibody, Ink4a/Arf antibody, Pctr1 antibody, p16(INK4a) antibody, p16INK4a antibody, p19 antibody, cyclin-dependent kinase inhibitor 2A antibody, cyclin dependent kinase inhibitor 2A antibody, Cdkn2a antibody, LOC100731972 antibody, LOC100340625 antibody, CDKN2A antibody

Background: Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development.

UniProt: Q64364

Pathways: Mitotic G1-G1/S Phases, Stem Cell Maintenance, Positive Regulation of Endopeptidase Activity, Autophagy, Positive Regulation of Response to DNA Damage Stimulus